Latest research on dexlansoprazole

TAK-390MR is an investigational for the treatment of acid related disorders.. TAK-390MR employs a new modified release (MR) technology on an enantiomer of lansoprazole.

dexlansoprazole side effects

Pantoprazole and dexlansoprazole were the only PPIs with a significant increased use post-safety communication (3.9% vs. 6.1% and 0.0% vs. 0.5%, respectively) ( [source, 2016]
dexlansoprazole also had a significant increase in the frequency of prescription (0.0% vs. 2.5%), the probability of which increased dramatically (OR = 72.55; p < 0.001) ( [source, 2016]
However, it should be noted that dexlansoprazole was initially approved in January 2009, making it difficult to establish a link between the increased use and the FDA Safety Communication. [source, 2016]
In the current study, the main decreases were observed for esomeprazole, followed by lansoprazole; which were partially replaced by Pantoprazole and dexlansoprazole. [source, 2016]
Pantoprazole and dexlansoprazole are the only two PPIs that had an increase in their prescription trends during the post-safety communication period. [source, 2016]
Finally, dexlansoprazole was launched in 2009, and market share progressively increased. [source, 2016]
The R-enantiomer is subsequently associated with decreased clearance compared to the S-enantiomer; however, this is not the sole mechanism that extends the effect of dexlansoprazole MR, as the elimination half-life of dexlansoprazole is similar to other PPIs (approximately 1–2 hours). [source, 2015]
All PPIs were found to decrease the peak plasma concentration of the active metabolite of clopidogrel; however, dexlansoprazole MR was found to have the least effect. [source, 2015]
Additionally, dexlansoprazole MR did not significantly decrease the area under the curve for Clopidogrel active metabolites, and more importantly, did not significantly interfere with the action of Clopidogrel on platelet function. [source, 2015]
A prospective, randomized, double-blind, placebo-controlled parallel group study comparing dexlansoprazole MR 30 mg to placebo found a significantly greater decrease in overall impairment of work productivity and impairment of regular activities in the dexlansoprazole MR group, as well as reduced number of impaired work hours when compared to placebo.29 [source, 2015]